Right ventricular (RV) failure is recognized to worsen patient outcomes in the setting of heart failure with reduced ejection fraction (HFrEF)-related pulmonary hypertension (PH), yet the investigators fall short in trying to identify and treat it. The current proposal will (1) determine the best clinical indicators of intrinsic RV myocyte contractile failure in humans with HFrEF-PH, (2) clarify underlying mechanisms, and (3) test novel treatments on RV myocytes. The long-term goal of this proposal will be to better identify and treat RV failure in humans suffering from HFrEF-PH.
Adult patients aged between 18 and 90 years of age
Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%)
Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure
Unable to interrupt VKA anticoagulation
Point of care International Normalized Ratio (INR) > 1.5
Pregnant patients
Acute hospitalization or decompensation within 2 weeks prior to study date
Johns Hopkins University
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator